ArticleJCO precision oncology2017
Identification and Functional Characterization of
Article in JCO precision oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Potential genetic modifiers for somatic EGFR mutation in lung cancer: a meta-analysis and literature review.BMC cancer · 2019Pooled it
- Novel Co-Occurrence of GermlineInternational journal of molecular sciences · 2026Article
- Article
- Lung cancer in patients who have never smoked - an emerging disease.Nature reviews. Clinical oncology · 2024Review
- GermlineJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Article
- A Nationwide Study on the Impact of Routine Testing forCancers · 2021Article
- Mutational landscape of multiple primary lung cancers and its correlation with non-intrinsic risk factors.Scientific reports · 2021Article
- Identification of the Unique Clinical and Genetic Features of Chinese Lung Cancer Patients WithFrontiers in oncology · 2021Article
- Profiling Oncogenic Germline Mutations in Unselected Chinese Lung Cancer Patients.Frontiers in oncology · 2021Article
- Significant Benefits of Osimertinib Against Adenosquamous Carcinoma Harboring Germline T790M Mutation.The oncologist · 2020Article
- NovelJCO precision oncology · 2018Article
- Targeting the EGFR signaling pathway in cancer therapy: What's new in 2023?Expert opinion on therapeutic targetsReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.